The transaction of Biocon Biologics marks the first US dollar bond issuance by a biopharmaceutical company in Asia-Pacific and the largest debut high-yield bond from India in the past decade.
Talwar Thakore & Associates (TT&A) represented Merrill Lynch (Singapore) Pte. Ltd., Citigroup Global Markets Singapore Pte. Ltd., The Hongkong and Shanghai Banking Corporation Limited, Singapore Branch, Standard Chartered Bank (Singapore) Limited, BNP Paribas, and Mizuho Securities (Singapore) Pte. Ltd. (the “Initial Purchasers”) in connection with Biocon Biologics Global plc’s issuance of USD 800 million 6.67% Senior Secured Notes due 2029.
This transaction is significant as it represents the first US dollar bond issuance by a biopharmaceutical company in the Asia-Pacific region and is the largest debut high-yield bond issuance from India in the past 10 years. It is also Biocon Group’s first overseas bond issuance.
TT&A Team:
- Rahul Gulati & Priyanka Kumar – Partners
- Saara Ahmed – Managing Associate
- Aakash Puttige – Senior Associate
- Shivani Iyer & Sushil Joon – Associates
IBM Acquires Prescinto to Enhance Renewable Energy Asset Management Capabilities
Share your news, articles, deals, columns, or press releases with us! Click the link to submit and join our platform today.
